-
Analysis of Antihypertensive Drugs Used in Shanghai Sample Hospitals
Time of Update: 2021-12-04
Top ten antihypertensive drugs commonly used in Shanghai sample hospitalsData source: China Pharmaceutical Industry Information Center Hospital Prescription Analysis System (RAS)The top four drugs with the most dosage are L-Amlodipine, Amlodipine, Valsartan, and Metoprolol.
-
What is the sales performance of multinational pharmaceutical companies after entering centralized procurement and medical insurance?
Time of Update: 2021-12-04
In the first nine months of this year, among the multinational pharmaceutical companies that performed well in China, for example, Novartis’s revenue in the Chinese market in the third quarter was US$839 million, a year-on-year increase of 19%; in the first nine months, the total revenue in the Chinese market was US$2.
-
What is the "money scene" of the pharmaceutical machinery industry when the payrolls of various industries are exposed?
Time of Update: 2021-12-04
The industry pointed out that industries with high wages generally conform to the direction of economic transformation and upgrading, and demand for talents is relatively strong, so wage levels and growth rates can maintain rapid growth .
-
The first three-generation BCR-ABL TKI in China!
Time of Update: 2021-12-04
After the first-generation BCR-ABL inhibitor Imatinib (Gleevec) and several subsequent second-generation drugs were launched, the clinical treatment of CML has made great progress and patients can achieve long-term survival .
The first indication developed by oribatinib is Bcr-Abl T315I mutant CML.
-
100 billion!
Time of Update: 2021-12-04
S. dollars to bet Japanese pharmaceutical company Daiichi Sankyo to jointly develop trastuzumab deruxtecan (DS-8201), an antibody conjugate targeting HER2;In 2020, Gilead announced the acquisition of the antibody drug company Immunomedics for US$21 billion, thus obtaining the first antibody-drug conjugate (ADC) Trodelvy;In 2021, Treasure Island announced that it will set up a wholly-owned subsidiary to engage in the research and development of anti-tumor ADC drugs.
-
Two pharmaceutical companies "marriage" to deepen their layout in the field of in vitro diagnostics
Time of Update: 2021-12-04
Public information shows that Zhongyuan Huiji is an enterprise specializing in the research and development, production, sales and technical services of in vitro diagnostic reagents and instruments.
China Heavy Pharmaceutical Holdings has been selling Zhongyuan Huiji's IVD products since 2019.
-
The consistency evaluation of generic drugs in my country is progressing smoothly, and a large number of products have been reviewed in November
Time of Update: 2021-12-04
Baiyunshan announced that the company's branch Baiyunshan Pharmaceutical General Factory received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration.
-
Bidding results of 45 drugs including amoxicillin are released, Qilu and Huahai become the biggest winners
Time of Update: 2021-12-04
Judging from the bid winning results, the average price reduction rate of Guangdong Union Centralized Purchasing is about 30%, and the price reduction rates of each variety in the A/B group are very different .
-
In the next five years, the outsourcing services provided by my country's pharmaceutical R&D service companies to the world may increase by an average annual rate of 25%
Time of Update: 2021-12-04
According to Frost&Sullivan's data, in 2020, China's medical manufacturing outsourcing (CMO) market will be approximately 4 billion U.
According to data from the China Medical Information Association, in the first half of this year, outsourcing services contributed 35% of the new drugs approved in China .
-
Fosun Pharma’s holding subsidiary withdraws the registration application for cromolyn sodium granules
Time of Update: 2021-12-04
As of the date of this announcement, cromolyn sodium oral preparations that have been marketed globally mainly include Sanofi's INTAL®, etc.
-
The State Food and Drug Administration issued two clinical trial data submission requirements and registration review guidelines
Time of Update: 2021-12-04
V. Form of submission The application materials related to clinical trial data of in vitro diagnostic reagents usually include the original database, analytical database, descriptive documents and program codes (if any).
-
Jinan, Shandong: Strive to reach 17 billion yuan in output value of Chinese medicine industry by 2023
Time of Update: 2021-12-04
By 2023, the operating income of the Chinese medicine health service industry will reach 3 billion yuan; by 2025, it will exceed 4 billion yuan .
In 2020, the operating income of the traditional Chinese medicine industry in Jinan will reach 11.
-
The latest development of disputes between Huadong Medicine and its subsidiaries
Time of Update: 2021-12-04
Huadong Medicine directly pointed out that its medical beauty subsidiary Huadong Ningbo was controlled by the management, refused to list company management audits, and operated related transactions, etc.
The continued operation of East China Ningbo would cause significant losses to the interests of shareholders.
-
Since November, a number of Class 1 new drugs from domestic pharmaceutical companies have been clinically approved
Time of Update: 2021-12-04
At present, the company has nearly 60 innovative drug projects under development, and 14 category 1 new drugs are in the clinical application and above stage, and 4 of them are already on the market.
-
The ADC track starts racing, and the competition for popular targets will become increasingly fierce
Time of Update: 2021-12-04
For example, Zhenbaodao Pharmaceutical recently announced that the company intends to establish a wholly-owned subsidiary in Hangzhou, Zhejiang Province, to invest in the construction of the company’s Hangzhou biopharmaceutical project, to engage in the research and development of anti-tumor ADC drugs, and to establish other subsidiaries, including settlement centers and sales.
-
The reshuffle of the pharmacy industry is accelerating, and single pharmacies will face major challenges
Time of Update: 2021-12-04
Therefore, the industry predicts that under the huge transformation and upgrading pressure of the current increase in industry concentration, a large number of monomer pharmacies will be eliminated at an accelerated pace.
-
These questions still need to be answered under the screen of oral anti-coronavirus drugs
Time of Update: 2021-12-04
▲Different stages of the new coronavirus replication cycle, Paxlovid targeted protease cleavage step (step 5 in the figure), molnupiravir targeted RNA replication and translation (step 6 in the figure) (picture source: reference [6])The rapid development of these two oral antiviral drugs is expected to provide new tools for the treatment of patients with COVID-19.
-
FGFR4 is very popular!
Time of Update: 2021-12-04
➢ ICP-105The development company is Nuocheng Jianhua, an orally effective and selective FGFR4 inhibitor, which is mainly clinically directed to hepatocellular carcinoma with excessive activation of the FGFR4 pathway; in September 2018, the phase I trial of advanced solid tumors was initiated .
-
Pfizer is looking for a new CFO, Frank, who has served for 15 years, is leaving
Time of Update: 2021-12-04
With Pfizer creating the single-product mRNA vaccine with the highest annual sales in history, Frank D'Amelio retired and announced that he would step down as the company's CFO and executive vice president of global supply .
-
Treating a variety of neurological diseases about 2.6 billion US dollars to help develop selective GPCR agonists
Time of Update: 2021-12-04
Recently, Neurocrine Biosciences and Sosei Heptares announced a strategic cooperation and licensing agreement to jointly develop new selective muscarinic receptor agonists for the treatment of schizophrenia, dementia and other neurological diseases .
